This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Evogene (EVGN) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Evogene (EVGN) delivered earnings and revenue surprises of 7.14% and 66.59%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Mirum Pharmaceuticals, Inc. (MIRM) delivered earnings and revenue surprises of -94.12% and 4.23%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Fate Therapeutics (FATE) delivered earnings and revenue surprises of 21.05% and 97.18%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Here's Why Evogene (EVGN) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does Evogene (EVGN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is Compugen (CGEN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Compugen (CGEN) and Evogene (EVGN) have performed compared to their sector so far this year.
Bears are Losing Control Over Evogene (EVGN), Here's Why It's a 'Buy' Now
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Evogene (EVGN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Evogene (EVGN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
Evogene (EVGN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Evogene (EVGN) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Evogene (EVGN) delivered earnings and revenue surprises of 10.53% and 15.07%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
TScan Therapeutics, Inc. (TCRX) delivered earnings and revenue surprises of 32.89% and 16.05%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of -20.51% and 54.73%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of 55.05% and 2,085.45%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Cidara Therapeutics (CDTX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of -75% and 46.90%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Evogene (EVGN) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Evogene (EVGN) delivered earnings and revenue surprises of 6.25% and 26.32%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Ikena Oncology, Inc. (IKNA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ikena Oncology, Inc. (IKNA) delivered earnings and revenue surprises of 15.22% and 8.21%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Telesis Bio (TBIO) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Telesis Bio (TBIO) delivered earnings and revenue surprises of 2.63% and 14.65%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
BioCardia, Inc. (BCDA) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of -30.77% and 81.18%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Avidity Biosciences, Inc. (RNA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Avidity Biosciences, Inc. (RNA) delivered earnings and revenue surprises of 17.78% and 7.15%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Evogene (EVGN) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Evogene (EVGN) delivered earnings and revenue surprises of 66.67% and 20%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Guardant Health (GH) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Guardant Health (GH) delivered earnings and revenue surprises of 2.86% and 1.17%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
All You Need to Know About Evogene (EVGN) Rating Upgrade to Strong Buy
by Zacks Equity Research
Evogene (EVGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Evogene (EVGN) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Evogene (EVGN) delivered earnings and revenue surprises of 20% and 79.23%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Roivant Sciences Ltd. (ROIV) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Roivant Sciences Ltd. (ROIV) delivered earnings and revenue surprises of -2.44% and 86.73%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Wave Life Sciences (WVE) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Wave Life Sciences (WVE) delivered earnings and revenue surprises of 12.50% and 94.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Clearside Biomedical, Inc. (CLSD) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of -425% and 98.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Fulcrum Therapeutics, Inc. (FULC) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Fulcrum Therapeutics, Inc. (FULC) delivered earnings and revenue surprises of 19.35% and 45.86%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?